California Stem Cell Acquires Cancer Stem Cell Therapy Program

California Stem Cell, Inc. expands therapeutics program to include a cell therapy for malignant melanoma.

IRVINE, Calif.--(BUSINESS WIRE)-- California Stem Cell (CSC) announced today that it has acquired a cancer stem cell program that is currently focused on the treatment of metastatic melanoma. The treatment represents a novel approach to treating malignancy.

The central concept behind this treatment is immunization against antigens via cells derived from the patient’s own blood that are then exposed to the patient’s own irradiated cancer cells, and subsequently administered in a series of injections. Significantly improved survival and time to recurrence has been demonstrated in an ongoing randomized Phase II trial, laying the groundwork for an effective treatment for melanoma and other cancers.

California Stem Cell was selected by Hoag Memorial Hospital Presbyterian as an ideal successor to continue the program and explore commercialization of this technology, which was developed over 20 years of translations, bench-to-bedside, laboratory and clinical research, due to CSC’s world-class cell culture personnel and facilities, in-house highly experienced regulatory team, and science-driven approach to increasing process efficiencies. The program is in alignment with CSC’s core competencies and transferred to CSC laboratories in Irvine October 1, 2011.

“CSC is very excited to be moving into the cancer space and active Phase II clinical trials with acquisition of this program,” said Chris Airriess, CSC’s COO. “Hoag’s decision to transition the program to CSC to advance this treatment through late clinical development shows great stewardship and we will continue to develop this program as a high priority.”

This acquisition has triggered plans to expand CSC’s Irvine, CA office and GMP manufacturing facility.

About California Stem Cell

California Stem Cell, Inc. (CSC) is an Irvine, CA based company which has developed proprietary methods to generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes. CSC is able to supply its human cell populations to companies and institutions worldwide for use in the development of therapies, efficacy screening or the creation of toxicity profiles for candidate drugs, and experimental research tools.

CSC is currently focused on the development of stem cell based therapies for spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s Disease), and metastatic cancers.

To learn more about California Stem Cell please visit:

Follow us on Twitter:


California Stem Cell, Inc.
Matt Bayless, +1 949-725-1750
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Oncology  Research  Science



Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.